Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2CNS 1

Conditions

Stomach Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Adenocarcinoma of the Stomach 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × GC1118 × Gastrointestinal × Clear all
NCT04077255 2022-11-30

EGFR-targeted Therapy for Gastric Cancer

National Cancer Center, Korea

Phase 2 Unknown
19 enrolled
Gastrointestinal

Adenocarcinoma of the Stomach

NCT02352571 2016-07-06

Safety Study of GC1118 (Recombinant Human Anti-EGFR Antibody) in Patients With Advanced Solid Cancer

GC Biopharma Corp

Phase 1 Unknown
72 enrolled
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡